Growth hormone peptides compared
Sermorelin vs tesamorelin
Two growth hormone-releasing hormone analogs, with each figure tied to its own label or study.
A review describes sermorelin as the shortest synthetic peptide with the full biological activity of GHRH, and the Egrifta WR label describes tesamorelin as a synthetic analog of human growth hormone-releasing factor.1,2 Prescribing text for sermorelin on RxList gives 11 to 12 minutes, and the Egrifta WR label 11 minutes for tesamorelin.3,2
Tesamorelin is labelled in the US as Egrifta WR for excess abdominal fat in HIV-infected adults with lipodystrophy, and FDA states that the US Geref products, 0.5 mg and 1.0 mg base per vial, were discontinued and not withdrawn for reasons of safety or effectiveness.2,4
| Fact | Sermorelin | Tesamorelin |
|---|---|---|
| What it is | The shortest synthetic peptide with the full biological activity of GHRH1 | A synthetic analog of human growth hormone-releasing factor: its 44 amino acid sequence with a hexenoyl moiety2 |
| How it comes | Geref, by subcutaneous injection; discontinued in the US, not for reasons of safety or effectiveness3,4 | An 11.6 mg vial, for subcutaneous injection2 |
| Half-life | 11 minutes in healthy subjects after a single subcutaneous dose, on the US label2 | |
| Studied doses | ||
| Status | FDA: the US Geref products were discontinued, not withdrawn for reasons of safety or effectiveness4. WADA names sermorelin among GHRH analogues in S2, prohibited at all times6 | US label: excess abdominal fat in HIV-infected adults with lipodystrophy2. WADA names tesamorelin among GHRH analogues, prohibited at all times6 |
Last reviewed . Sources are listed below.
How they differ
The Egrifta WR label gives an absolute bioavailability of less than 4% after a 2 mg subcutaneous dose of the earlier 1 mg/vial formulation, and states that exposure from 1.28 mg of Egrifta WR is similar to that 2 mg dose; a sermorelin prescribing text on RxList gives about 6% after subcutaneous dosing.2,3 The Egrifta WR label states that it is not indicated for weight loss management, as it has a weight neutral effect.2
Logged in Milligram
- Sermorelin: Too few people logged it to show a share.
- Tesamorelin: 11% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.
What is not known
The Egrifta WR label states that the effects of prolonged elevations in IGF-1 levels are unknown.2 A review states that the standard dosage of sermorelin has not been directly compared with somatropin, and that sermorelin given by infusion or in 3 divided doses gave smaller gains in height velocity than once-daily somatropin in children; a sermorelin prescribing text on RxList states that no metabolism studies have been performed in humans.1,3
References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. Journal article (review), 1999. PMID 18031173
- Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection, prescribing information. regulatory label, 2026. DailyMed label
- RxList. Sermorelin Acetate (Sermorelin): Side Effects, Uses, Dosage, Interactions, Warnings. Drug label text, 2001. rxlist.com
- Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Regulator notice, 2013. govinfo.gov
- Irish Medicines Board. Summary of Product Characteristics: Geref 50 (sermorelin acetate). Regulator document, 2006. assets.hpra.ie
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Regulator document, 2026. wada-ama.org